HUMAW - Humacyte, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

HUMAW

HUMACYTE, INC.

NASDAQ

$0.00

▼ DOWN 78.05% (-0.00)

KEY STATISTICS

Market Cap$1.08 M

52w High$0.23

52w Low$0.00

Dividend Yield—

Frequency—

P/E-0.00

Volume0

Shares Out.1.20B

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Laura E. Niklason

COMPENSATION 2026

Salary$500,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$5,348

Total$1,749,088

ABOUT

SECTOR

Healthcare

WENT PUBLIC

December 1, 2020

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

184

UPCOMING EARNINGS

DateNov 6, 2026

DayFriday

Rev. Est.$769.38K

NOV

FRI

PRICE

$0.00 ▲ UP 48.35% (+$73.38)

—

No price history available for HUMAW over this range.

About Humacyte, Inc.

https://www.humacyte.com ↗

Humacyte, Inc. develops off-the-shelf, bioengineered human tissues and acellular vessels for vascular repair, reconstruction, and cellular therapy across multiple medical areas.

INDUSTRY

Biotechnology

A PRODUCT HUMACYTE, INC. IS KNOWN FOR

Symvess™ (acellular tissue engineered vessel-tyod)

Symvess™ is Humacyte's bioengineered human acellular vessel for universal vascular repair, especially in extremity arterial trauma when autologous veins aren't viable.